Literature DB >> 30168660

STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility.

Irina T Zaharieva1, Anna Sarkozy1,2, Pinki Munot1,2, Adnan Manzur1,2, Gina O'Grady3,4, John Rendu5, Eduardo Malfatti6, Helge Amthor7,8, Laurent Servais9, J Andoni Urtizberea10, Osorio Abath Neto11,12, Edmar Zanoteli11, Sandra Donkervoort12, Juliet Taylor13, Joanne Dixon14, Gemma Poke15, A Reghan Foley12, Chris Holmes2, Glyn Williams2, Muriel Holder16, Sabrina Yum17, Livija Medne18, Susana Quijano-Roy8,19, Norma B Romero6, Julien Fauré5, Lucy Feng1, Laila Bastaki20, Mark R Davis21, Rahul Phadke1,2, Caroline A Sewry1,22, Carsten G Bönnemann12, Heinz Jungbluth23,24,25, Christoph Bachmann25, Susan Treves25,26, Francesco Muntoni1,2,27.   

Abstract

SH3 and cysteine-rich domain-containing protein 3 (STAC3) is an essential component of the skeletal muscle excitation-contraction coupling (ECC) machinery, though its role and function are not yet completely understood. Here, we report 18 patients carrying a homozygous p.(Trp284Ser) STAC3 variant in addition to a patient compound heterozygous for the p.(Trp284Ser) and a novel splice site change (c.997-1G > T). Clinical severity ranged from prenatal onset with severe features at birth, to a milder and slowly progressive congenital myopathy phenotype. A malignant hyperthermia (MH)-like reaction had occurred in several patients. The functional analysis demonstrated impaired ECC. In particular, KCl-induced membrane depolarization resulted in significantly reduced sarcoplasmic reticulum Ca2+ release. Co-immunoprecipitation of STAC3 with CaV 1.1 in patients and control muscle samples showed that the protein interaction between STAC3 and CaV 1.1 was not significantly affected by the STAC3 variants. This study demonstrates that STAC3 gene analysis should be included in the diagnostic work up of patients of any ethnicity presenting with congenital myopathy, in particular if a history of MH-like episodes is reported. While the precise pathomechanism remains to be elucidated, our functional characterization of STAC3 variants revealed that defective ECC is not a result of CaV 1.1 sarcolemma mislocalization or impaired STAC3-CaV 1.1 interaction.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  STAC3; congenital myopathy; excitation-contraction coupling; malignant hyperthermia

Mesh:

Substances:

Year:  2018        PMID: 30168660     DOI: 10.1002/humu.23635

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

1.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

2.  Neurogenetic fetal akinesia and arthrogryposis: genetics, expanding genotype-phenotypes and functional genomics.

Authors:  Gina Ravenscroft; Joshua S Clayton; Fathimath Faiz; Padma Sivadorai; Di Milnes; Rob Cincotta; Phillip Moon; Ben Kamien; Matthew Edwards; Martin Delatycki; Phillipa J Lamont; Sophelia Hs Chan; Alison Colley; Alan Ma; Felicity Collins; Lucinda Hennington; Teresa Zhao; George McGillivray; Sondhya Ghedia; Katherine Chao; Anne O'Donnell-Luria; Nigel G Laing; Mark R Davis
Journal:  J Med Genet       Date:  2020-10-15       Impact factor: 6.318

3.  Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine.

Authors:  Jean-François Desaphy; Concetta Altamura; Savine Vicart; Bertrand Fontaine
Journal:  J Neuromuscul Dis       Date:  2021

4.  Molecular interactions of STAC proteins with skeletal muscle dihydropyridine receptor and excitation-contraction coupling.

Authors:  Dmitry Shishmarev; Emily Rowland; Shouvik Aditya; Srinivasan Sundararaj; Aaron J Oakley; Angela F Dulhunty; Marco G Casarotto
Journal:  Protein Sci       Date:  2022-05       Impact factor: 6.993

5.  L-Carnitine ameliorates congenital myopathy in a tropomyosin 3 de novo mutation transgenic zebrafish.

Authors:  Po-Jui Hsu; Horng-Dar Wang; Yung-Che Tseng; Shao-Wei Pan; Bonifasius Putera Sampurna; Yuh-Jyh Jong; Chiou-Hwa Yuh
Journal:  J Biomed Sci       Date:  2021-01-12       Impact factor: 8.410

6.  Effects of Remimazolam and Propofol on Ca2+ Regulation by Ryanodine Receptor 1 with Malignant Hyperthermia Mutation.

Authors:  Tomoyuki Watanabe; Hirotsugu Miyoshi; Yuko Noda; Soshi Narasaki; Atsushi Morio; Yukari Toyota; Hiroshi Kimura; Keiko Mukaida; Toshimichi Yasuda; Yasuo M Tsutsumi
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

Review 7.  Molecular and cellular basis of genetically inherited skeletal muscle disorders.

Authors:  James J Dowling; Conrad C Weihl; Melissa J Spencer
Journal:  Nat Rev Mol Cell Biol       Date:  2021-07-13       Impact factor: 94.444

Review 8.  Anaesthesia and neuromuscular disorders: what a neurologist needs to know.

Authors:  Heinz Jungbluth; Nicol C Voermans; Luuk R van den Bersselaar; Marc M J Snoeck; Madelief Gubbels; Sheila Riazi; Erik-Jan Kamsteeg
Journal:  Pract Neurol       Date:  2020-10-27

9.  A case report of malignant hyperthermia in a patient with myotonic dystrophy type I: A CARE-compliant article.

Authors:  Seon Woo Yoo; Seon Ju Baek; Dong-Chan Kim; A Ram Doo
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 10.  Skeletal muscle CaV1.1 channelopathies.

Authors:  Bernhard E Flucher
Journal:  Pflugers Arch       Date:  2020-03-28       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.